
Trump Admin Sets Deadline for Eliminating 8 Food Dyes in US Foods
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
U.S. health officials announced Tuesday that they will begin phasing out petroleum-derived artificial color additives from the national food supply—a move that could lead to major reformulations of many vividly colored products found on store shelves.
At a news conference, Food and Drug Administration (FDA) Commissioner Marty Makary outlined the agency's plan to eliminate eight synthetic food dyes by the end of 2026. As part of the initiative, the FDA will set clear industry standards and timelines for transitioning to natural color alternatives. In the coming weeks, the agency will also revoke approval for any dyes no longer in production and begin the process of removing the remaining synthetic dyes currently on the market.
The eight synthetic food dyes targeted for removal are: Red No. 40 (Allura Red AC); Yellow No. 5 (Tartrazine); Yellow No. 6 (Sunset Yellow FCF); Blue No. 1 (Brilliant Blue FCF); Blue No. 2 (Indigo Carmine); Green No. 3 (Fast Green FCF); Citrus Red No. 2; Orange B.
A woman holds a sign reading "MAHA Moms" at a press conference with US Secretary of Health and Human Services Robert F. Kennedy Jr. and Food and Drug Administration Commissioner (FDA) Martin Makary on the...
A woman holds a sign reading "MAHA Moms" at a press conference with US Secretary of Health and Human Services Robert F. Kennedy Jr. and Food and Drug Administration Commissioner (FDA) Martin Makary on the intent of the FDA to phase out the use of petroleum-based synthetic dyes in the nation's food supply, at the Department of Health and Human Services in Washington, DC, on April 22, 2025.The measure is a key component of Health Secretary Robert F. Kennedy Jr.'s broader "Make America Healthy Again" agenda.
The change marks a substantial shift for U.S. food manufacturers, many of whom would need to reformulate products using natural color alternatives.
Advocates for public health have long pushed for the removal of synthetic dyes, citing research—though mixed—that links these additives to neurobehavioral issues in children, such as hyperactivity and attention deficits. While the FDA has consistently maintained that approved color additives are safe, the agency acknowledges that "the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives."
Currently, the FDA authorizes the use of 36 color additives, including eight synthetic dyes. In January, the agency declared that Red 3—a dye found in certain candies, baked goods, and pharmaceuticals—would be banned by 2028 due to its link to cancer in laboratory animals.
The targeted dyes are widely used in American food products. In contrast, many companies in Canada and Europe have already transitioned to natural alternatives, partly due to regulations that require warning labels on foods containing artificial colors.
A growing number of U.S. states, including California and West Virginia, have recently passed laws restricting or banning artificial dyes and other additives from school meals and, in some cases, from the broader food supply.
This is a developing news story and will be updated as more information is available.
Reporting by the Associated Press contributed to this story.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
We recently published . MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare stocks. MannKind Corporation (NASDAQ:MNKD)'s most recent milestone is its push to expand the use of its rapid-acting inhaled insulin, Afrezza, to pediatric patients. In August 2025, the company submitted a supplemental Biologics License Application to the FDA for use in children ages 4–17, supported by positive Phase 3 INHALE-1 trial results presented at major diabetes conferences. A regulatory decision is expected in Q4 2025. Clinical data from both pediatric (INHALE-1) and adult (INHALE-3) studies have reinforced Afrezza's efficacy and safety across age groups. These advances have also helped the business gain attention among investors looking at the best healthcare stocks. Beyond Afrezza, MannKind Corporation (NASDAQ:MNKD) is advancing its pipeline in respiratory and rare diseases. MNKD-101, an inhaled clofazimine for nontuberculous mycobacterial lung disease, is progressing ahead of schedule in its global Phase 3 ICoN-1 trial. MNKD-201, a therapy for idiopathic pulmonary fibrosis, is set to enter Phase 2 testing by the end of 2025. Copyright: nicoletaionescu / 123RF Stock Photo To support these initiatives, the business secured up to $500 million in non-dilutive financing from Blackstone in August 2025. This funding will accelerate the potential launch of pediatric Afrezza, expand its commercial capabilities, and advance its clinical programs. Together, these developments position MannKind Corporation (NASDAQ:MNKD) for growth in both diabetes care and specialty lung disease markets. While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
2 hours ago
- Yahoo
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare stocks. ImmunityBio, Inc. (NASDAQ:IBRX) is among the best healthcare stocks. It is a clinical-stage biotech company developing advanced immunotherapies and vaccines targeting cancers and infectious diseases by activating immune cells such as natural killer and T cells. A key recent milestone is the FDA-approved immunotherapy drug ANKTIVA for bladder cancer, specifically for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS). ANKTIVA, designated a Breakthrough Therapy, is expanding its clinical use, notably with the Michael E. DeBakey VA Medical Center in Houston becoming one of the first VA hospitals to administer the treatment to veterans, a population at higher bladder cancer risk. In Q2 2025, ImmunityBio, Inc. (NASDAQ:IBRX) reported a 60% revenue growth quarter-over-quarter, reaching $26.4 million and a year-to-date total of approximately $43 million. This growth is driven by increased commercial momentum post-approval and supported by an $80 million capital raise in July 2025 to fuel ongoing development and expansion. ImmunityBio, Inc. (NASDAQ:IBRX) is transitioning from a clinical-stage biotech to a commercial-stage company with ANKTIVA's expanding adoption, including recent UK regulatory approval for ANKTIVA plus BCG. The drug addresses an underserved cancer indication with the potential to reduce invasive treatments like cystectomy, backed by clinical data showing durable bladder preservation up to 36 months in responders. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

9 hours ago
Draft of new 'MAHA' report suggests RFK Jr. won't target pesticides
The draft of an upcoming government report suggesting ways to improve the health of American children does not recommend severe restrictions on pesticides and ultra-processed foods, according to a copy of the document obtained by ABC News. The draft's language, if left unchanged, would constitute a win for the agriculture industry and a potential setback for Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and his "Make America Healthy Again" (MAHA) allies, who have railed against the use of chemical additives in America's food supply, arguing that they harm children. A person familiar with the draft cautioned that the language could still change before it's released to the public. "Unless officially released by the administration, any document purporting to be the MAHA report should be dismissed as speculative literature," White House deputy press secretary Kush Desai said in response to ABC News' request for comment. An HHS spokesperson declined to verify the document's authenticity. The New York Times first reported details of the new draft report. The report will be the second "MAHA" report released by the Trump administration following one published in May. Both were composed by officials in the White House and across different federal agencies, including Kennedy's HHS. The May report detailed the factors officials said were worsening the health of American children and called for a second report, within 100 days, to recommend policies to address those factors. The earlier report -- which was dogged by the revelation that some studies it cited were nonexistent -- cited damning statistics about the effect of chemical food additives, tying them to cancer and developmental disorders. The draft of the new report does not signal any intention to eliminate pesticides from America's food. Instead, the draft calls for "more targeted and precise pesticide applications" and research programs that would "help to decrease pesticide volumes." The report also stated the Environmental Protection Agency "will work to ensure that the public has awareness and confidence in EPA's robust pesticide review procedures and how that relates to the limiting of risk for users and the general public." Regarding ultra-processed foods, the new report states only that HHS, the U.S. Department of Agriculture and the Food and Drug Administration would work to develop a "government-wide definition for 'ultra-processed food.'" In his January confirmation hearing, Kennedy declared that "something is poisoning the American people, and we know that the primary culprits are changing food supply, a switch to highly chemical intensive processed foods." Meanwhile, some "MAHA" influencers have loudly demanded changes to the country's food supply, putting their faith in Kennedy to leverage his position of power to uproot the agriculture industry. But this summer, agriculture groups lobbied intensely against the inclusion of anti-pesticide recommendations in the new report. They appeared to find an ally in Secretary of Agriculture Brooke Rollins, who indicated to reporters this month that the upcoming report would spare pesticides. "There is no chance that our current system of agriculture can survive without those crop protection tools," she said at a press conference in a Washington. "I feel very confident that his, and our, commitment to make sure that farmers are at the table remains paramount, and that the report will reflect that."